NEA Management Company, LLC — 13F Holdings & Portfolio
CIK 1512848 · latest 13F-HR filed 2026-08-14
NEA Management Company, LLC manages $1.59B in 13F-reported U.S. long-equity assets across 26 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are TRVI (15.53%), MBX (12.56%), GLUE (11.72%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 1 new position and exited 1; 15 existing positions rose in reported value and 8 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- MBX Biosciences, Inc.$91.6M +84.9%
- Trevi Therapeutics, Inc.$88.9M +56.3%
- Monte Rosa Therapeutics, Inc.$59.6M +47.1%
- Zenas BioPharma, Inc.$23.5M +29.8%
- Savara, Inc.$17.1M +12.8%
Top Trims
- Celcuity Inc.-$81.9M -31.4%
- Spyglass Pharma, Inc.-$27.0M -14.1%
- CVRx, Inc.-$9.1M -47.6%
- ORIC Pharmaceuticals, Inc.-$7.6M -14.5%
- Inventiva SA-$2.5M -31.1%
NEA Management Company, LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Trevi Therapeutics, Inc. | TRVI | 89532M101 | $246.6M | 15.53% | 13,222,228 | SH |
| 2 | MBX Biosciences, Inc. | MBX | 55287L101 | $199.5M | 12.56% | 3,614,486 | SH |
| 3 | Monte Rosa Therapeutics, Inc. | GLUE | 61225M102 | $186.2M | 11.72% | 7,692,298 | SH |
| 4 | Celcuity Inc. | CELC | 15102K100 | $179.0M | 11.27% | 1,710,561 | SH |
| 5 | Spyglass Pharma, Inc. | SGP | 85220G109 | $164.6M | 10.36% | 7,392,301 | SH |
| 6 | Savara, Inc. | SVRA | 805111101 | $150.7M | 9.49% | 24,471,264 | SH |
| 7 | Zenas BioPharma, Inc. | ZBIO | 98937L105 | $102.1M | 6.43% | 4,023,219 | SH |
| 8 | Coursera, Inc. | COUR | 22266M104 | $72.6M | 4.57% | 12,867,769 | SH |
| 9 | Aurinia Pharmaceuticals, Inc. | AUPH | 05156V102 | $67.4M | 4.24% | 3,969,834 | SH |
| 10 | CRISPR Therapeutics AG | CRSP | H17182108 | $57.7M | 3.64% | 1,058,570 | SH |
| 11 | ORIC Pharmaceuticals, Inc. | ORIC | 68622P109 | $44.6M | 2.81% | 4,118,621 | SH |
| 12 | Phathom Pharmaceuticals, Inc. | PHAT | 71722W107 | $21.3M | 1.34% | 1,960,169 | SH |
| 13 | Korro Bio, Inc. | KRRO | 500946108 | $17.1M | 1.08% | 1,297,893 | SH |
| 14 | X4 Pharmaceuticals, Inc. | XFOR | 98420X103 | $15.1M | 0.95% | 3,233,743 | SH |
| 15 | Champions Oncology, Inc. | CSBR | 15870P307 | $10.6M | 0.66% | 1,713,720 | SH |
| 16 | Nkarta, Inc. | NKTX | 65487U108 | $10.1M | 0.64% | 3,568,781 | SH |
| 17 | CVRx, Inc. | CVRX | 126638105 | $10.0M | 0.63% | 1,954,440 | SH |
| 18 | Black Diamond Therapeutics, Inc. | BDTX | 09203E105 | $8.2M | 0.52% | 4,448,757 | SH |
| 19 | Karyopharm Therapeutics Inc. | KPTI | 48576U205 | $5.6M | 0.35% | 576,780 | SH |
| 20 | Inventiva SA | IVA | 46124U107 | $5.5M | 0.35% | 1,462,586 | SH |
| 21 | LeonaBio, Inc. | LONA | 04746L203 | $4.3M | 0.27% | 464,398 | SH |
| 22 | Senti Biosciences, Inc. | SNTI | 81726A209 | $4.2M | 0.26% | 3,775,615 | SH |
| 23 | Marker Therapeutics, Inc. | MRKR | 57055L206 | $2.4M | 0.15% | 1,625,678 | SH |
| 24 | OnKure Therapeutics, Inc. | OKUR | 68277Q105 | $2.2M | 0.14% | 478,548 | SH |
| 25 | ImageneBio, Inc. | IMA | 45175G207 | $295.0K | 0.02% | 50,005 | SH |
| 26 | Gossamer Bio, Inc. | GOSS | 38341P102 | $164.6K | 0.01% | 1,000,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $1.59B | 26 | 0001072613-26-000684 |
| 2026-03-31 | 2026-05-15 | $1.76B | 26 | 0001072613-26-000458 |
| 2025-12-31 | 2026-02-17 | $1.96B | 27 | 0001072613-26-000191 |
| 2025-09-30 | 2025-11-14 | $1.82B | 29 | 0000897069-25-001705 |
SUITE 600
TIMONIUM, MD 21093